What the FDA labels say about taking them together
Eslicarbazepine and oxcarbazepine
Eslicarbazepine's FDA label of November 10, 2023 names oxcarbazepine in its contraindications section, and oxcarbazepine's label names eslicarbazepine too. The oxcarbazepine label: “CONTRAINDICATIONS Oxtellar XR is contraindicated in patients with a known hypersensitivity to oxcarbazepine, to any of the components of Oxtellar XR, or to eslicarbazepine acetate.”
Check it at the source: the eslicarbazepine FDA label on DailyMed (effective November 10, 2023, Sumitomo Pharma America, Inc.); the oxcarbazepine FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation).
What does the eslicarbazepine label say about oxcarbazepine?
Eslicarbazepine label, contraindicationsCONTRAINDICATIONS APTIOM is contraindicated in patients with a hypersensitivity to eslicarbazepine acetate or oxcarbazepine [see Warnings and Precautions ( 5.2 , 5.3 , and 5.4 )]. Hypersensitivity to eslicarbazepine acetate or oxcarbazepine.
Eslicarbazepine label, warnings and precautionsPatients with a prior dermatologic reaction with oxcarbazepine, carbamazepine, or APTIOM should ordinarily not be treated with APTIOM [see Contraindications ( 4 )].
Source: FDA drug label (Aptiom), Sumitomo Pharma America, Inc., effective November 10, 2023 (SPL set 3d0c9554-eaeb-4694-8089-00133fcadce3), via openFDA; the full label on DailyMed
What does the oxcarbazepine label say about eslicarbazepine?
Oxcarbazepine label, contraindicationsCONTRAINDICATIONS TRILEPTAL is contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate [ see Warnings and Precautions (5.2, 5.3) ].
Oxtellar Xr label (Supernus Pharmaceuticals, Inc., October 22, 2025), contraindicationsCONTRAINDICATIONS Oxtellar XR is contraindicated in patients with a known hypersensitivity to oxcarbazepine, to any of the components of Oxtellar XR, or to eslicarbazepine acetate.
Source: FDA drug label (Oxtellar Xr, NDA202810), Supernus Pharmaceuticals, Inc., effective October 22, 2025 (SPL set aa610e56-1d1d-11e1-8bc2-0800200c9a66), via openFDA
Source: FDA drug label (Trileptal), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set 4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Eslicarbazepine | Oxcarbazepine | |
|---|---|---|
| Labeled for | Seizures and epilepsy | Seizures and epilepsy |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.68 per tablet 200 mg tablet | $0.167 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once